BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18513880)

  • 21. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
    Reardon DA; Fink KL; Mikkelsen T; Cloughesy TF; O'Neill A; Plotkin S; Glantz M; Ravin P; Raizer JJ; Rich KM; Schiff D; Shapiro WR; Burdette-Radoux S; Dropcho EJ; Wittemer SM; Nippgen J; Picard M; Nabors LB
    J Clin Oncol; 2008 Dec; 26(34):5610-7. PubMed ID: 18981465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme--a pilot study.
    Shinoda J; Sakai N; Hara A; Ueda T; Sakai H; Nakatani K
    J Neurooncol; 1997 Oct; 35(1):73-80. PubMed ID: 9266443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
    Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G
    Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of lenalidomide in solid tumors.
    Miller AA; Case D; Harmon M; Savage P; Lesser G; Hurd D; Melin SA
    J Thorac Oncol; 2007 May; 2(5):445-9. PubMed ID: 17473661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short course of radiation therapy in elderly patients with glioblastoma multiforme.
    Idbaih A; Taillibert S; Simon JM; Psimaras D; Schneble HM; Lopez S; Lang P; Toubiana T; Feuvret L; Delattre JY; Mazeron JJ
    Cancer Radiother; 2008 Dec; 12(8):788-92. PubMed ID: 19046921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
    Prasad E; Viswanathan PN; Rangad VF; Pavamani S; Ram TS
    Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):488-93. PubMed ID: 19386478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
    Beauchesne PD; Taillandier L; Bernier V; Carnin C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
    Ferroli P; Broggi M; Franzini A; Maccagnano E; Lamperti M; Boiardi A; Broggi G
    Neurosurgery; 2006 Aug; 59(2):E433-4; discussion E433-4. PubMed ID: 16883158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
    Chang JE; Khuntia D; Robins HI; Mehta MP
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
    Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
    J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.